Location History:
- Islip, GB (2000)
- Islip Oxfordshire, GB (2003)
- Islip, Oxon OX5 2SF, GB (2003)
- Appleton, GB (2005 - 2006)
- Oxon, GB (2001 - 2007)
- The Oxford Science Park, GB (2007)
- Oxford, GB (2004 - 2022)
Company Filing History:
17 out of 53 
3 out of 5 
2 out of 2 
Years Active: 2000-2022
Title: Alan John Kingsman: A Pioneer in Innovative Therapeutics
Introduction: Alan John Kingsman, based in Oxford, GB, is a prominent inventor and researcher known for his remarkable contributions to the field of biotechnology. With an impressive portfolio of 22 patents, Kingsman has made significant advancements in the development of therapies aimed at treating various neurological disorders, including Parkinson's disease.
Latest Patents: Among his latest innovations are the patents related to catecholamine enzyme fusions. These innovative constructs encompass nucleotide sequences that encode tyrosine hydroxylase (TH), GTP-cyclohydrolase I (CH1), and Aromatic Amino Acid Dopa Decarboxylase (AADC). The groundbreaking work involves linking these sequences to create fusion proteins such as TH-CH1 and AADC-TH. Moreover, these constructs are incorporated into viral vectors that hold the potential to revolutionize treatments for Parkinson's disease, offering new hope for patients suffering from this debilitating condition.
Career Highlights: Kingsman's career is marked by his influential role in notable companies such as Oxford Biomedica Limited and Oxford Biomedica, Inc. His tenure at these institutions has allowed him to lead innovative projects that bridge the gap between research and practical medical applications. His extensive experience in the biotechnology sector has established him as a key figure in the development of effective therapeutic solutions.
Collaborations: Throughout his career, Kingsman has collaborated with several esteemed professionals, including Susan Mary Kingsman and Kyriacos Andreou Mitrophanous. These partnerships have further enriched his research, facilitating the exchange of ideas and innovations that contribute to advancing the field of gene therapy and biotechnology.
Conclusion: Alan John Kingsman's ongoing dedication to innovation and invention in biotechnology marks him as an influential inventor in the realm of therapeutic development. His inventive work, particularly in the area of enzyme fusions, demonstrates the important intersection of science and medicine, with the potential to significantly impact the treatment of neurological diseases. As he continues to build upon his impressive body of work, the future looks promising for both his contributions and their applications in the medical community.